相似文献
1
Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.
Arch Med Sci. 2020 Nov 20;17(1):266-274. doi: 10.5114/aoms.2020.101042. eCollection 2021.
2
An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
Math Biosci. 2015 Apr;262:117-24. doi: 10.1016/j.mbs.2015.01.011. Epub 2015 Feb 3.
3
Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.
Genet Mol Res. 2015 Jun 11;14(2):6413-8. doi: 10.4238/2015.June.11.17.
4
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Int J Med Sci. 2016 Apr 28;13(5):365-73. doi: 10.7150/ijms.14989. eCollection 2016.
5
Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
Tumour Biol. 2017 Mar;39(3):1010428317695946. doi: 10.1177/1010428317695946.
6
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Leukemia. 2004 Mar;18(3):401-8. doi: 10.1038/sj.leu.2403257.
7
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Chem Biol Interact. 2015 Dec 5;242:195-201. doi: 10.1016/j.cbi.2015.10.004. Epub 2015 Oct 9.
8
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1.
9
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell. 2002 Aug;2(2):117-25. doi: 10.1016/s1535-6108(02)00096-x.
10
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
Cancer Genet Cytogenet. 2005 Mar;157(2):104-8. doi: 10.1016/j.cancergencyto.2004.06.014.
引用本文的文献
1
Overcoming Chemoresistance in Cancer: The Promise of Crizotinib.
Cancers (Basel). 2024 Jul 7;16(13):2479. doi: 10.3390/cancers16132479.
2
Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Int J Mol Sci. 2023 Apr 23;24(9):7730. doi: 10.3390/ijms24097730.
3
2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
Molecules. 2022 Jan 26;27(3):804. doi: 10.3390/molecules27030804.
本文引用的文献
1
STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.
Arch Med Sci. 2019 Sep;15(5):1163-1175. doi: 10.5114/aoms.2018.77733. Epub 2018 Aug 23.
2
Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance.
Mini Rev Med Chem. 2019;19(4):333-345. doi: 10.2174/1389557518666181017124854.
3
The molecular details of cytokine signaling via the JAK/STAT pathway.
Protein Sci. 2018 Dec;27(12):1984-2009. doi: 10.1002/pro.3519.
4
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7.
5
F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors.
ACS Med Chem Lett. 2017 Apr 6;8(6):632-635. doi: 10.1021/acsmedchemlett.7b00084. eCollection 2017 Jun 8.
6
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.
Blood. 2016 Dec 8;128(23):2671-2682. doi: 10.1182/blood-2015-11-679928. Epub 2016 Sep 12.
7
Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.
Curr Drug Targets. 2017;18(4):377-388. doi: 10.2174/1389450117666160615074120.
8
High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
Int J Hematol. 2016 Sep;104(3):358-67. doi: 10.1007/s12185-016-2028-9. Epub 2016 Jun 6.
9
BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Oncotarget. 2016 Apr 26;7(17):24436-54. doi: 10.18632/oncotarget.8332.
10
Drug Therapy in the Progressed CML Patient with multi-TKI Failure.
Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015014. doi: 10.4084/MJHID.2015.014. eCollection 2015.
Zotero 插件
